| Name | benazeprilat |
|---|---|
| Synonyms |
Benazril Impurity 3(Benazril Impurity C)
(2S)-2-[[(3S)-1-(Cboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazin-3-yl]amino]-4-phenylbutanoic Acid (Benazrilat) Benazril Imp C (3S)-3-[[(S)-1-Carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid Benazril Impurity 3 CGS14831|||CGS-14831|||CGS Benazril Impurity C (Disodium Salt) benazeprilate Benazril Impurity C/ Benazril Related Compund C (Benazrilat) (3S)-3-[[(S)-1-Cboxy-3-phenylpropyl]amino]-2 Benazril Related Compound C ((3S)-3-[[(1S)-1-cboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-ox Benazril Related Compound C 5-tetrahydro-2-oxo-1H-1-benzazine-1-acetic acid (2S)-2-[[(3S)-1-(Cboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazin-3-yl]amino]-4-phenylbutanoi Benazepril Related CoMpound C L-Tyrosine-d Benazril hydrochloride impurity C Benazril Impurity C (Benazril Related Compound C, Benazrilat) BENAZRILAT HCL HYDRATE Benazepril Related Compound C (50 mg) ((3S)-3-[[(1S)-1- carboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo- 1H-1-benzazepine]-1-acetic acid) Benazril Impurity C 1H-1-Benzazepine-1-acetic acid,3-(1S)-1-carboxy-3-phenylpropylamino-2,3,4,5-tetrahydro-2-oxo-,(3S) Benazril Imp. C : (3S)-3-[[(1S)-1-Cboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazine-1-acetic Acid 1-carboxymethyl-3S-(1S-carboxy-3-phenylpropylamino)-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one CGS-14831 Cibacen (S)-2-(((S)-1-(cboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azin-3-yl)amino)-4-phenylbutanoic acid 3-[1-carboxy-3-phenyl-(1S)-propylamino]-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid (3S)-3-[[(S)-1-Cboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazine-1-acetic acid (2S)-2-[[(3S)-1-(Cboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazin-3-yl]amino]-4-phenylbutanoic Acid 1H-1-Benzazine-1-acetic acid, 3-(1S)-1-cboxy-3-phenylpropylamino-2,3,4,5-tetrahydro-2-oxo-, (3S) (3S)-3-[[(1S)-1-carboxy-3-phenylpropyl]aMino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine]-1-acetic acid BENAZRILAT 1-carboxymethyl-3-1-carboxy-3-phenyl-(1S)-propylamino-2,3,4,5-tetrahydro-1H-(3S)-1-benzazepine-2-one Benazrilat Impurity C Benazril Related Compound C (50 mg) ((3S)-3-[[(1S)-1- cboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo- 1H-1-benzazine]-1-acetic acid) (3S)-3-[[(1S)-1-cboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazine]-1-acetic acid BENAZRILAT HYDROCHLORIDE HYDRATE Benazril Diacid (Benaz. Impurity C) BenazrilatQ: What is Benazrilat Q: What is the CAS Number of Benazrilat Q: What is the storage condition of Benazrilat Q: What e the applications of Benazrilat |
| Description | Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monotherapy and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line treatment in reducing various pathologies associated with CV risk and secondary end-organ damage[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Human Endogenous Metabolite |
| In Vivo | Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect[2]. Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI[3]. Animal Model: Male SHR (14-16 weeks of age, 250-350 g)[2]. Dosage: 10 mg/kg Administration: I.V; once a day for 2 days. Result: Produced hypotensive effect. Animal Model: Beagle dogs (12.0-19.5 kg)[3]. Dosage: 0.7 mg/kg Administration: P.O, once a day for 5 days. Result: Effected systemic RAAS peptides. |
| References |
| Density | 1.34 g/cm3 |
|---|---|
| Boiling Point | 711.3ºC at 760 mmHg |
| Melting Point | 270-272ºC |
| Molecular Formula | C22H24N2O5 |
| Molecular Weight | 396.43600 |
| Flash Point | 384ºC |
| Exact Mass | 396.16900 |
| PSA | 106.94000 |
| LogP | 2.55050 |
| Index of Refraction | 1.643 |
| RIDADR | NONH for all modes of transport |
|---|
|
~68%
86541-78-8 |
| Literature: Watthey; Stanton; Desai; Babiarz; Finn Journal of Medicinal Chemistry, 1985 , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
|
~%
86541-78-8 |
| Literature: Journal of Medicinal Chemistry, , vol. 28, # 10 p. 1511 - 1516 |
| Precursor 6 | |
|---|---|
| DownStream 0 | |